Ian Kramer
Showing 1–2 of 2 transcripts.
- Milken Institute1h 0m
New Pathways to Neuroscience Breakthroughs
Rick Berke, Cara Altimus, Jeffrey Borenstein, Niranjan Bose, Johannes Streffer, Mike Belville, David Mongeau, Janet Knupp, Jing Lu, Ian Kramer, Anna McAllister
A panel of experts highlighted the critical gap in preventing and treating brain disorders despite projections that dementia cases will double over the next three decades. To address historical stagnation and corporate retreat, the discussion emphasized a strategic pivot toward diverse biological hypotheses, early biomarker detection, and philanthropic de-risking led by organizations like the Gates Foundation. This approach aims to overcome diagnostic delays and therapeutic failures by integrating real-world data, stem cell modeling, and patient-centric outcomes to accelerate the development of rapid-acting treatments.
- Milken Institute59 min
Finding a Cure for the Cost of Durable Therapies
Dan Mendelson, Yvonne Greenstreet, Joe Grogan, Michael Sherman, Mark Skinner, John Birch, Ian Kramer, Jupiter Lazmar
A panel of industry leaders, payers, and advocates highlighted the systemic friction between transformative gene therapies and traditional commercial models that rely on high-volume patient pools to amortize R&D costs. Participants detailed pricing pressures for one-time cures and chronic durable treatments while showcasing innovative risk-sharing agreements, such as Alnylam's outcomes-based pilot with Harvard Pilgrim Health Care, to manage financial exposure. Addressing these challenges, the group called for federal policy reform to eliminate "best price" disincentives and the adoption of flexible valuation frameworks that integrate patient-reported outcomes to prevent insurance affordability crises.